{"indexed":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T04:43:09Z","timestamp":1568436189937},"reference-count":3,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"URL":"http:\/\/www.springer.com\/tdm","start":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T00:00:00Z","timestamp":1533254400000},"delay-in-days":0,"content-version":"tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s12020-018-1699-9","type":"article-journal","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T05:12:45Z","timestamp":1533273165000},"page":"487-489","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":"Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis","prefix":"10.1007","volume":"62","author":[{"ORCID":"http:\/\/orcid.org\/0000-0001-9232-4042","authenticated-orcid":false,"given":"Stergios A.","family":"Polyzos","sequence":"first","affiliation":[]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,8,3]]},"reference":[{"key":"1699_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/TCRM.S24239","volume":"8","author":"AD Anastasilakis","year":"2012","unstructured":"A.D. Anastasilakis, K.A. Toulis, S.A. Polyzos, C.D. Anastasilakis, P. Makras, Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther. Clin. Risk Manag. 8, 295\u2013306 (2012)","journal-title":"Ther. Clin. Risk Manag."},{"key":"1699_CR2","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1530\/EJE-18-0056","volume":"179","author":"AD Anastasilakis","year":"2018","unstructured":"A.D. Anastasilakis, S.A. Polyzos, P. Makras, Therapy of endocrine disease: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur. J. Endocrinol. 179, R31\u2013r45 (2018)","journal-title":"Eur. J. Endocrinol."},{"key":"1699_CR3","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s10067-014-2562-x","volume":"33","author":"GS Breuer","year":"2014","unstructured":"G.S. Breuer, M. Ehrenfeld, I. Rosner, A. Balbir-Gurman, D. Zisman, S. Oren, D. Paran, Late-onset neutropenia following rituximab treatment for rheumatologic conditions. Clin. Rheumatol. 33, 1337\u20131340 (2014)","journal-title":"Clin. Rheumatol."}],"container-title":"Endocrine","original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-018-1699-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1699-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1699-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T07:06:54Z","timestamp":1565161614000},"score":1.0,"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,3]]},"references-count":3,"journal-issue":{"published-print":{"date-parts":[[2018,11]]},"issue":"2"},"alternative-id":["1699"],"URL":"http:\/\/dx.doi.org\/10.1007\/s12020-018-1699-9","relation":{"cites":[]},"ISSN":["1355-008X","1559-0100"],"container-title-short":"Endocrine","assertion":[{"value":"10 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S.A.P. has received a lecture fee from AMGEN. E.T. has received lectures fees, research grants from AMGEN and is a member of the steering committee of AMGEN.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol received an exemption from the ethics committee of Medical School of Aristotle University of Thessaloniki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the individual participant included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}